TrialLancet (London, England)2021

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R W Emary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.